| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_03e4a831cb1c0b7d927bf8ee2eaf06b8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_812ae01e41ecc148f5e59026a288d9fd |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2800-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-0331 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-8509
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-0276
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-82 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01K67-027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 |
| filingDate |
2007-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bf2b14a6c5ab691584a03c968d441374
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_924ea798d1059b5690edb362567d4264 |
| publicationDate |
2008-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2008216180-A1 |
| titleOfInvention |
Animal model for cancer, methods of producing the same and associated methods of use |
| abstract |
A transgenic animal having a somatic cell in which at least one allele of an endogenous p53 and Pten gene is functionally disrupted is provided. The cell of the animal may be heterozygous or, more preferably, homozygous for the gene disruptions. The animals of the invention can be used to evaluate the efficacy of novel therapeutics and to identify novel points of therapeutic intervention for cancer. In certain embodiments, the transgenic animal is a transgenic mouse having functionally disrupted endogenous p53 and Pten genes. This mouse can be used to identify agents that inhibit the development of cancers, namely bladder cancers in humans in vivo. Nucleic acid constructs for functionally disrupting an endogenous p53 and Pten gene in a host cell, recombinant vectors including the nucleic acid construct, and host cells into which the nucleic acid construct has been introduced are also encompassed by the invention |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10251376-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10655144-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9901081-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9901080-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012177927-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103045584-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110241085-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114982718-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10378002-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9968076-B2 |
| priorityDate |
2006-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |